---

Federal Register announcement published Aug. 15, 1995, by the NIH

---

[Federal Register: August 15, 1995 (Volume 60, Number 157)]
[Notices]
[Page 42171]

-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes Of Health

Prospective Grant of Exclusive License: Immunologic Enhancement
With Intermittent Interleukin-2 Therapy

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.
-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive world-wide license to practice the invention embodied in
U.S. Patent Application SN 08/063,315 (U.S. Patent 5,419,900) entitled
``Immunologic Enhancement with Intermittent Interleukin-2 Therapy'' and
related U.S. and foreign patent applications to Chiron Corporation of
Emeryville, CA. The patent rights in this invention have been assigned
to the United States of America.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
It is anticipated that this license may be limited to all therapeutic
applications including treatment of HIV infection and AIDS. This
prospective exclusive license may be granted unless within 60 days from
the date of this published notice, NIH receives written evidence and
argument that establishes that the grant of the license would not be
consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
The patent application describes the continuous intermittent
infusion of interleukin-2, alone or in combination with retroviral
therapy, into a patient as a means of enhancing the patient's immune
system. The ability of this therapy to stimulate immune function may
have advantages in any disease state in which interleukin-2 plays a
role in the associated immune response, and may therefore be useful in
the treatment of HIV infections and AIDS, as well as for the attendant
opportunistic infections that occur in AIDS patients.

ADDRESSES: Requests for a copy of this patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Steven M. Ferguson, Technology Licensing
Specialist, Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852.
Telephone: (301) 496-7735; Facsimile: (301) 402-0220; E-mail: Steve--
Ferguson@NIH.GOV. Applications for a license filed in response to this
notice will be treated as objections to the grant of the contemplated
license. Only written comments and/or applications for a license which
are received by NIH on or before October 16, 1995, will be considered.
Comments and objections submitted in response to this notice will not
be made available for public inspection, and, to the extent permitted
by law, will not be released under the Freedom of Information Act, 5
U.S.C. 552. A signed Confidential Disclosure Agreement will be required
to receive a copy of the patent application.

Dated: August 2, 1995.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 95-20044 Filed 8-14-95; 8:45 am]
BILLING CODE 4140-01-P